GRI Bio, Inc. (GRI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

GRI Bio, Inc. (GRI) closed at USD 1.40 on 2026-10-14, a change of -97.4 % over the past year, with a market capitalization of USD 3.06M.

GRI Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

GRI Bio, Inc. key figures

Previous close

USD 1.40 (2026-10-14)

1-year change

-97.4 %

Market cap

USD 3.06M

Enterprise value

USD -7.84M

P/E ratio (trailing)

-0.11

P/E ratio (forward)

-0.70

EPS (trailing)

-13.29

EPS (forward)

-2.00

PEG ratio

n/a

Price to book

0.30

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.13

Employees

3

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About GRI Bio, Inc.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for GRI Bio, Inc. and compare it with other stocks.